title: Clinical interest of point-of-care pharmacogenomic testing: clopidogrel behind warfarin.
authors.forename: Payman
authors.initials: P
authors.lastname: Shahabi
authors.forename: Gérard
authors.initials: G
authors.lastname: Siest
authors.forename: Sophie
authors.initials: S
authors.lastname: Visvikis-Siest
mesh_terms: D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D054316:Biomarkers, Pharmacological; D001777:Blood Coagulation / Q000187:drug effects; D000077144:Clopidogrel; D065729:Cytochrome P-450 CYP2C9; D006801:Humans; D006899:Mixed Function Oxygenases / Q000235:genetics*; D010597:Pharmacogenetics; D019095:Point-of-Care Systems; D013988:Ticlopidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D064417:Vitamin K Epoxide Reductases; D014859:Warfarin / Q000008:administration & dosage*
chemical_list: D054316:Biomarkers, Pharmacological; D014859:Warfarin; D000077144:Clopidogrel; D006899:Mixed Function Oxygenases; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases; D064417:Vitamin K Epoxide Reductases; D013988:Ticlopidine